Literature DB >> 28736378

[Optimization of emollient formulation for treating atopic dermatitis by skin physiological index testing].

Song-Gen Huang1, Xi-Xiao Yang, Li-Qian Mo, Xian-Yi Zhou.   

Abstract

OBJECTIVE: To optimize the formulation of an emollient for treatment of atopic dermatitis prepared using ceramide, sodium hyaluronate, paeonol, and camellia-seed oil.
METHODS: The emollients with different ratios of the 4 components were designed according to the L9(34)orthogonal table with 4 factors and 3 levels. The efficacy of the prepared emollients was tested in 4-6 week-old BALB/c mouse models of atopic dermatitis to determine the optimal formulation of the emollient by evaluating skin water content, transepidermal water loss (TEWL), pharmacodynamics and skin irritation.
RESULTS: Range analysis of the orthogonal table and analysis of variance showed that ceramide and camellia seed oil contents had the greatest impact on the skin water content and TEWL, respectively, and the optimal composition of the emollient contained the 4 components at the ratios of D1E1F1G1. Pharmacodynamic experiments showed that at high, medium and low doses, the emollient with the optimal formulation significantly improved the skin water content, pH and TEWL in the mice (P<0.05) with similar effects in the positive control group (P>0.05) and a skin irritation test score of 0.
CONCLUSION: The emollient we prepared can significantly improve skin water content, pH and TEWL in the mouse model of atopic dermatitis without skin irritations.

Entities:  

Year:  2017        PMID: 28736378      PMCID: PMC6765524     

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  8 in total

1.  Rectal-specific microbicide applicator: evaluation and comparison with a vaginal applicator used rectally.

Authors:  Alex Carballo-Diéguez; Rebecca Giguere; Curtis Dolezal; José Bauermeister; Cheng-Shiun Leu; Juan Valladares; Lisa C Rohan; Peter A Anton; Ross D Cranston; Irma Febo; Kenneth Mayer; Ian McGowan
Journal:  AIDS Behav       Date:  2014-09

2.  Inhibitory effect of Psidium guajava water extract in the development of 2,4-dinitrochlorobenzene-induced atopic dermatitis in NC/Nga mice.

Authors:  Jae Ho Choi; Bong Hwan Park; Hyung Gyun Kim; Yong Pil Hwang; Eun Hee Han; Sun Woo Jin; Jong Kwon Seo; Young Chul Chung; Hye Gwang Jeong
Journal:  Food Chem Toxicol       Date:  2012-05-17       Impact factor: 6.023

3.  Treatment with DHA/EPA ameliorates atopic dermatitis-like skin disease by blocking LTB4 production.

Authors:  Shinya Yoshida; Koji Yasutomo; Toshiyuki Watanabe
Journal:  J Med Invest       Date:  2016

4.  Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice.

Authors:  H Matsuda; N Watanabe; G P Geba; J Sperl; M Tsudzuki; J Hiroi; M Matsumoto; H Ushio; S Saito; P W Askenase; C Ra
Journal:  Int Immunol       Date:  1997-03       Impact factor: 4.823

5.  Phosphoproteomic analysis of cells treated with longevity-related autophagy inducers.

Authors:  Martin V Bennetzen; Guillermo Mariño; Dennis Pultz; Eugenia Morselli; Nils J Færgeman; Guido Kroemer; Jens S Andersen
Journal:  Cell Cycle       Date:  2012-05-01       Impact factor: 4.534

6.  A new moisturizer containing physiologic lipid granules alleviates atopic dermatitis.

Authors:  Jung-Im Na; Jae-Sung Hwang; Hye-Jin Park; Do-Hoon Kim; Won-Seok Park; Sang-Woong Youn; Chang-Hun Huh; Kyoung-Chan Park
Journal:  J Dermatolog Treat       Date:  2010-01       Impact factor: 3.359

7.  Short-chain ceramides decrease skin barrier properties.

Authors:  J Novotný; B Janůsová; M Novotný; A Hrabálek; K Vávrová
Journal:  Skin Pharmacol Physiol       Date:  2008-12-17       Impact factor: 3.479

8.  Sustained exogenous expression of therapeutic levels of IFN-gamma ameliorates atopic dermatitis in NC/Nga mice via Th1 polarization.

Authors:  Kayoko Hattori; Makiya Nishikawa; Kanitta Watcharanurak; Akihiko Ikoma; Kenji Kabashima; Hiroyasu Toyota; Yuki Takahashi; Rei Takahashi; Yoshihiko Watanabe; Yoshinobu Takakura
Journal:  J Immunol       Date:  2010-01-27       Impact factor: 5.422

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.